OTC Markets OTCQX - Delayed Quote USD

Microbix Biosystems Inc. (MBXBF)

Compare
0.2750 +0.0130 (+4.96%)
At close: December 20 at 11:32:05 AM EST
Loading Chart for MBXBF
DELL
  • Previous Close 0.2620
  • Open 0.2750
  • Bid 0.2696 x --
  • Ask 0.2829 x --
  • Day's Range 0.2750 - 0.2750
  • 52 Week Range 0.2000 - 0.3280
  • Volume 17,500
  • Avg. Volume 10,148
  • Market Cap (intraday) 37.357M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 9.17
  • EPS (TTM) 0.0300
  • Earnings Date Feb 12, 2025 - Feb 17, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

www.microbix.com

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: MBXBF

View More

Performance Overview: MBXBF

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MBXBF
2.14%
S&P/TSX Composite index
17.37%

1-Year Return

MBXBF
8.33%
S&P/TSX Composite index
18.04%

3-Year Return

MBXBF
49.07%
S&P/TSX Composite index
18.61%

5-Year Return

MBXBF
16.16%
S&P/TSX Composite index
44.16%

Compare To: MBXBF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MBXBF

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    37.60M

  • Enterprise Value

    33.09M

  • Trailing P/E

    10.72

  • Forward P/E

    17.24

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.32

  • Price/Book (mrq)

    1.89

  • Enterprise Value/Revenue

    2.03

  • Enterprise Value/EBITDA

    6.30

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MBXBF

View More

Company Insights: MBXBF

Research Reports: MBXBF

View More

People Also Watch